Form 4: Teva Director Rosemary Crane Reports Share Transactions
SEC Form 4 Filing
Director Rosemary Crane reports the acquisition of 21,108 ordinary shares of Teva Pharmaceutical Industries through the vesting of restricted share units.
Summary
- Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd., reported a transaction on June 15, 2024.
- The transaction involved the acquisition of 21,108 ordinary shares through the vesting of restricted share units.
- Following the transaction, Crane directly owns 103,615 ordinary shares.
- The restricted share units were granted on June 15, 2023, and vested on June 15, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted |
| 06/15/2024 | Date of transaction: acquisition of shares through vesting of restricted share units |
| 06/17/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.